Eyal Levit, MD
MOHS-Micrographic Surgery · Brooklyn, NYNPI 1801813621
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,609 of the $21,581 with a category attached, or 67.7%. It is spread thinly across 39 manufacturers, the largest accounting for just 19.4%. Reporting peaked in 2024 at $7,041 and has fallen 77.0% since, to $1,622 in 2025.
Across 732 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dermavant Sciences, Inc.$4K
- Amgen$2K
- Johnson & Johnson$2K
- Merz North America, Inc.$2K
- Pfizer$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $9K from 33 others
What the payments were for
- Consulting fees$4,33020%
- Speaking & faculty fees$1,7408%
- Food & beverage$14,60968%
- Education$9024%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,581 in reported general payments places this provider in the 85th percentile of 75 mohs-micrographic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 37 | $755,762 |
| OpzeluraRuxolitinib Phosphate | 339 | $670,472 |
| ErivedgeVismodegib | 38 | $508,757 |
| Dupixent PenDupilumab | 136 | $504,060 |
| TremfyaGuselkumab | 24 | $320,174 |
| XeljanzTofacitinib Citrate | 41 | $230,146 |
| OtezlaApremilast | 40 | $191,657 |
| ZoryveRoflumilast | 206 | $173,497 |
| VtamaTapinarof | 68 | $95,848 |
| JubliaEfinaconazole | 48 | $59,669 |
| Diclofenac Sodium | 405 | $48,919 |
| Ivermectin | 122 | $38,335 |
| FinaceaAzelaic Acid | 84 | $35,216 |
| Halobetasol Propionate | 605 | $32,957 |
| EucrisaCrisaborole | 33 | $32,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $869 | $670,472339 claims |
| Genentech USA, Inc.Erivedge | $743 | $508,75738 claims |
| Johnson & JohnsonTremfya | $2,238 | $320,17424 claims |
| PfizerXeljanz, Eucrisa | $1,374 | $262,74574 claims |
| AmgenOtezla | $2,354 | $191,65740 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $536 | $173,497206 claims |
| Dermavant Sciences, Inc.Vtama | $4,186 | $95,84868 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $234 | $59,66948 claims |
| LEO Pharma Inc.Finacea | $444 | $35,21684 claims |
| Almirall LLCCordran | $98 | $10,20213 claims |
| Dermira, Inc.Qbrexza | $71 | $9,05314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 mohs-micrographic surgery providers in New York.
Other mohs-micrographic surgery in Brooklyn
- Michael ShapiroBrooklyn$4K
- Juliya FisherBrooklyn$4K
- Sherry HsiungBrooklyn$2K
- Daniel SiegelSmithtown$450K
- Sherrif IbrahimVictor$412K
- Kavita MariwallaWest Islip$221K
- Ellen MarmurNew York$186K
- Kenneth MarkSouthampton$91K
- Michael TassavorNew York$55K
- Jane YooNew York$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.